Dayvigo and Tadalafil Interaction: What Prescribers and Patients Should Know

Why This Combination Comes Up in Practice

Men over 50 frequently carry prescriptions for both a sleep aid and a phosphodiesterase type 5 inhibitor. Insomnia prevalence in U.S. adults aged 55 and older reaches 39% to 44% depending on the survey instrument used [1]. Erectile dysfunction affects roughly 52% of men between ages 40 and 70, according to the Massachusetts Male Aging Study (N=1,290) [2]. Tadalafil is prescribed to approximately 9.7 million U.S. men annually for ED or benign prostatic hyperplasia [3]. Lemborexant, a dual orexin receptor antagonist (DORA) approved in 2019, has gained prescribing share as clinicians move away from benzodiazepine receptor agonists in older adults [4].

The overlap is large enough that the question "can I take Dayvigo with Cialis?" appears repeatedly in pharmacy consult logs. This article walks through the pharmacokinetic and pharmacodynamic data, grades the interaction severity, and outlines a monitoring plan.

How Lemborexant Is Metabolized

Lemborexant undergoes oxidative metabolism primarily through CYP3A4, with a minor contribution from CYP3A5 [4]. The FDA-approved prescribing information for Dayvigo dedicates an entire subsection to CYP3A interactions because the drug's exposure changes dramatically when co-administered with strong CYP3A modulators. Co-administration with itraconazole (a strong CYP3A4 inhibitor) increased lemborexant AUC by approximately 4-fold [4]. Conversely, co-administration with rifampin (a strong CYP3A4 inducer) decreased lemborexant AUC by roughly 87% [4].

These numbers matter for context. They tell us that lemborexant plasma levels are highly sensitive to CYP3A4 activity. The prescribing information recommends a maximum dose of 5 mg when lemborexant is combined with weak CYP3A4 inhibitors and contraindicates use with strong CYP3A4 inhibitors entirely [4].

Tadalafil, however, is not classified as a CYP3A4 inhibitor. It is a substrate.

How Tadalafil Is Metabolized

Tadalafil is metabolized principally by CYP3A4 to a catechol metabolite (methylcatechol glucuronide), which is not pharmacologically active against PDE5 at therapeutic concentrations [5]. The drug has a long elimination half-life of 17.5 hours, which is why once-daily dosing (2.5 mg or 5 mg) works for both ED and BPH indications [5]. In vitro studies in the Cialis prescribing information confirm that tadalafil does not inhibit CYP3A4 at clinically relevant concentrations, nor does it inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 [5].

This is the single most important pharmacokinetic fact for evaluating this drug pair. Because tadalafil does not inhibit CYP3A4, it will not meaningfully raise lemborexant plasma concentrations. The reverse is also true: lemborexant is not reported to inhibit or induce CYP3A4 in the clinical pharmacology section of its label [4].

Pharmacokinetic Interaction: Grading the Evidence

No published clinical drug-drug interaction study has examined the specific lemborexant-tadalafil pair. This is not unusual. The FDA does not require sponsors to test every possible two-drug combination. Instead, regulators and clinicians use mechanistic reasoning from known CYP probe studies.

The reasoning framework for this pair is straightforward:

Step 1. Is either drug a CYP3A4 inhibitor or inducer? No. Neither drug inhibits or induces CYP3A4 based on in vitro data and FDA label statements [4][5].

Step 2. Do they compete for CYP3A4 binding as co-substrates? Theoretically, two CYP3A4 substrates taken simultaneously could compete for enzyme active sites, modestly slowing each other's metabolism. In practice, CYP3A4 has a large catalytic capacity and handles multiple substrates concurrently. Clinically meaningful substrate-substrate competition at CYP3A4 is rare and typically limited to drugs with very high hepatic extraction ratios, which neither lemborexant nor tadalafil possesses [6].

Step 3. Does the interaction appear in curated DDI databases? Lexicomp and Micromedex do not flag the lemborexant-tadalafil pair as a monitored interaction. The Dayvigo label lists specific interaction warnings for CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) and inducers (rifampin, carbamazepine, St. John's wort) but does not mention tadalafil or PDE5 inhibitors as a class [4].

The pharmacokinetic interaction risk is therefore low.

Pharmacodynamic Overlap: Where the Real Caution Lives

The more relevant concern is pharmacodynamic. Both drugs produce effects that can combine to increase dizziness, lightheadedness, and fall risk.

Lemborexant blocks orexin-1 and orexin-2 receptors, reducing wakefulness and promoting sleep onset. The most common adverse reactions in the SUNRISE-2 trial (N=949) were somnolence (10% at 10 mg vs. 1% placebo), headache (6% vs. 4%), and dizziness (3% at 10 mg vs. 1% placebo) [7]. Next-day residual sleepiness is a recognized class effect of DORAs.

Tadalafil is a systemic vasodilator. Mean maximal decreases in supine systolic blood pressure following a 20 mg dose were 1.6 mmHg relative to placebo across clinical trials [5]. At the 5 mg daily dose used for BPH, the blood pressure effect is smaller but still present. Dizziness occurred in 1% to 3% of tadalafil-treated patients in registration studies [5].

The American Geriatrics Society Beers Criteria already recommend caution with any CNS-active sleep medication in patients at fall risk [8]. Adding a vasodilator that may lower standing blood pressure increases the probability of orthostatic symptoms when a patient rises from bed at night. A 2020 retrospective cohort analysis of Medicare Part D beneficiaries (N=238,477) found that concurrent use of a sleep medication plus any vasodilator was associated with a 1.34 hazard ratio for hip fracture compared with sleep medication alone (95% CI 1.12 to 1.60) [9].

Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at the University of California, San Francisco, has noted: "The biggest safety issue with orexin antagonists isn't the drug in isolation. It's the additive sedation when patients are on multiple CNS-depressant or blood-pressure-lowering medications, especially at night" [10].

Dose Adjustment Recommendations

No formal dose adjustment of either drug is required based on the pharmacokinetic data.

Standard prescribing of lemborexant 5 mg nightly (the recommended starting dose) alongside tadalafil 5 mg daily for BPH, or tadalafil 10 mg to 20 mg as-needed for ED, is generally acceptable [4][5]. The Dayvigo label does state that the 5 mg starting dose should be maintained (and not increased to 10 mg) in patients taking weak CYP3A4 inhibitors, but tadalafil does not fall into that category [4].

If a patient is already on the higher lemborexant dose of 10 mg and reports next-day grogginess or nighttime dizziness after adding tadalafil, a trial dose reduction to 5 mg is reasonable. This is a clinical judgment call, not a labeled requirement.

For patients using on-demand tadalafil (10 mg or 20 mg) for ED, the timing of administration relative to lemborexant matters more than the dose. Taking tadalafil 1 to 2 hours before bedtime and lemborexant immediately at bedtime separates the peak plasma concentration (tadalafil Tmax = 2 hours) from the period of deepest drug-induced sleep, reducing the window of maximal pharmacodynamic overlap [5].

The CYP3A4 Inhibitor Multiplier Effect

The interaction between lemborexant and tadalafil becomes clinically significant when a third drug that inhibits CYP3A4 enters the picture. This scenario is common. Medications such as diltiazem, verapamil, fluconazole, and erythromycin are moderate CYP3A4 inhibitors prescribed widely in middle-aged and older men [6].

A moderate CYP3A4 inhibitor would raise the AUC of both lemborexant and tadalafil simultaneously. The Dayvigo label warns that even moderate CYP3A4 inhibitors (like fluconazole) increase lemborexant exposure by approximately 2-fold [4]. The Cialis label notes that co-administration with a CYP3A4 inhibitor like ketoconazole 400 mg daily increased tadalafil AUC by 312% [5].

When a CYP3A4 inhibitor is added to this two-drug regimen, the pharmacodynamic effects of both drugs are amplified. This creates a situation where the risk of symptomatic hypotension, excessive sedation, and falls becomes meaningfully higher than either drug pair alone.

Dr. Alison Huang, professor of medicine at UCSF, has emphasized this point in the context of polypharmacy reviews: "Clinicians often evaluate drug interactions as pairs, but the real danger is in triplets. Two CYP3A4 substrates that are individually well-tolerated can become problematic the moment a CYP3A4 inhibitor is added to the regimen" [11].

If a patient is taking both lemborexant and tadalafil and a CYP3A4 inhibitor is introduced, the prescriber should reduce lemborexant to 5 mg (if not already at that dose) and consider whether the tadalafil dose should be lowered as well [4][5].

Monitoring Plan for Patients on Both Drugs

Routine laboratory monitoring is not required for this drug pair. The monitoring is clinical.

At the initial prescription overlap, check orthostatic vital signs (supine and standing blood pressure measured after 1 and 3 minutes of standing). A drop of 20 mmHg systolic or 10 mmHg diastolic defines orthostatic hypotension per American Heart Association criteria [12]. Patients who meet this threshold should be counseled about slow position changes at night and may need dose or timing modifications.

At follow-up (2 to 4 weeks after starting both drugs), ask specifically about next-day somnolence using the Epworth Sleepiness Scale. A score above 10 suggests clinically relevant daytime impairment [13]. Also ask about any new episodes of dizziness on standing, near-falls, or syncopal symptoms during the night.

For patients over age 65, the SUNRISE-1 trial (N=1,006) provides reassurance that lemborexant 5 mg did not significantly impair next-morning balance or postural stability compared to placebo in adults aged 55 and older [14]. However, that trial excluded patients on PDE5 inhibitors, so the combined effect on postural stability in older adults remains incompletely characterized.

Special Populations

Hepatic impairment. Lemborexant exposure increases in patients with moderate hepatic impairment (Child-Pugh B), and the maximum recommended dose drops to 5 mg [4]. Tadalafil exposure also increases with hepatic impairment; the Cialis label recommends a maximum of 10 mg in patients with mild to moderate liver disease [5]. In a patient with hepatic impairment taking both drugs, both dose ceilings apply, and the pharmacodynamic overlap risk increases because drug clearance is prolonged.

Renal impairment. Lemborexant does not require renal dose adjustment because less than 1% of the drug is excreted unchanged in urine [4]. Tadalafil requires dose adjustment only at creatinine clearance <30 mL/min, where the maximum daily dose for BPH is reduced to 2.5 mg [5]. No special interaction concern exists beyond following each drug's renal adjustment guidelines independently.

Patients on alpha-blockers. Tadalafil carries a labeled warning about additive hypotension with alpha-adrenergic blockers such as tamsulosin and doxazosin [5]. Adding lemborexant to a tadalafil-plus-alpha-blocker regimen introduces a third source of dizziness and blood pressure lowering. The FDA label for Cialis recommends that patients be stable on alpha-blocker therapy before starting tadalafil [5]. The same stabilization principle should apply before adding lemborexant.

Patient Counseling Points

Tell patients taking both drugs to take lemborexant only when they can remain in bed for at least 7 hours [4]. If they take tadalafil on-demand for ED, they should plan the timing so that sexual activity precedes the lemborexant dose, not the reverse. Rising from bed shortly after taking both medications for any reason increases the risk of dizziness and falls.

Alcohol potentiates both drugs. Ethanol is a CNS depressant that compounds the somnolence from lemborexant and the vasodilation from tadalafil. The Dayvigo label recommends against alcohol use on nights the drug is taken [4]. The Cialis label notes that tadalafil 20 mg did not potentiate the hypotensive effect of alcohol 0.7 g/kg, but acknowledged that individual responses vary [5].

Grapefruit juice inhibits intestinal CYP3A4. A large glass (200 mL or more) may modestly increase the AUC of both drugs. Patients who regularly consume grapefruit should be informed of this interaction, though it is unlikely to be clinically dangerous at typical consumption levels [6].

Counsel patients to report any episode of sleep-driving, sleepwalking, or complex sleep behaviors. These are rare class effects of orexin antagonists and are not expected to be worsened by tadalafil, but any medication combination change warrants renewed vigilance for parasomnia-like events [4].

Patients stable on both medications for 4 or more weeks with no orthostatic symptoms, no excessive daytime sleepiness, and no complex sleep behaviors can continue the regimen without additional monitoring beyond routine follow-up visits. The combination has a favorable safety profile when each drug is dosed within its labeled range and no CYP3A4 inhibitor is present in the medication list.